10.17.25 -- STREAM Edition: Takeda's Amy Shaw On Scaling Cell Therapy Manufacturing

Join our webinar to explore case studies on optimizing microbial fermentation and media strategies. Thermo Fisher Scientific experts share real-world approaches to media formulation and process conditions, featuring Bacto™ CD Supreme FPM — a chemically defined medium that can support process scalability, enhance flexibility, and improve performance. View now >>

While Alnylam is well-equipped for rare and specialty conditions, broader public health issues such as hypertension and, potentially, Alzheimer’s, necessitate a shift in company mindset and a different commercialization approach. Alnylam’s strategic partnership with Roche for Zilebesiran will leverage the latter’s experience in CNS conditions and help to build Alnylam's capabilities for future large-scale opportunities. For 2025, Alnylam's top priorities include the launch of Amvuttra for cardiomyopathy and strengthening the company’s foundational commercial capabilities, such as AI, data generation, value-based agreements, and omnichannel marketing.

In this presentation, experts provide insight into transposase-mediated genome engineering, genetic quality control, and the maintenance of genetic stability in cell line generation.

With the DynaSpin Single-Use Centrifuge, minimalism is about intentionality. We designed our automated process with a simplified tubing setup and a substantial reduction in filter usage.

Takeda head of process development, Amy Shaw, explains what factors to consider when scaling up or scaling out cell therapy manufacturing.

Discover essential analytical techniques in biotherapeutics development, as well as explore ITC, DSC, and Rheology—powerful tools for understanding formulation, stability, and efficacy in drug development.

A novel cell lysis solution can improve rAAV recovery by rapidly rupturing cell membranes while remaining compatible with existing workflows. Discover a scalable and efficient lysis alternative.